The European Society
of Human Genetics

ESHG Webinar Series - Archive

ESHG webinar series - Archive

Here you can explore and watch recordings of past ESHG webinar episodes featuring leading experts in human genetics. Click on the YouTube links below to access each episode and revisit insightful discussions, presentations, and educational content at your convenience.

Recordings on YouTube

We are recording the webinars and making them available in the ESHG Educational Library on YouTube.

Watch past Episodes now! To the Webinar Playlist on the ESHG YouTube Channel

S1 E1 - Wednesday, February 26, 2025 (16:00 CET)

true

Malte Spielmann
University Hospital Schleswig-Holstein
Germany

The Dark Side of the Genome: Challenges and Opportunities in the Post-Genomic Era

Clinical genome sequencing has become a reality in most European countries. However, more than 50% of rare disease patients remain without a molecular diagnosis even after undergoing advanced genomic testing. One possible reason for this gap is the lack of focus on the "dark side" of the genome—the 98% that is non-coding—which is often overlooked when diagnosing patients or studying cancer biology.

In my presentation, I will discuss the role of non-coding mutations and structural variants in causing human disease. Our research aims to understand the pleiotropic effects of these mutations and structural variants during embryogenesis, as well as their impact on the 3D architecture of the genome.
To achieve these objectives, we leverage cutting-edge, high-throughput technologies during mouse embryonic development, including single-cell analysis, chromosome conformation capture techniques, and massively parallel reporter assays.

Watch now!

S1 E2 - Wednesday, March 26, 2025 (16:00 CET)

true

Nicola Whiffin
University of Oxford
United Kingdom

The non-coding exome in rare disease: from diagnosis to therapies

Over 300 million people worldwide have a rare disorder. Currently, less than half of all individuals with a rare disorder receive a genetic diagnosis and even if the genetic cause of disease is known, over 95% of rare disorders have no specific treatments available. Current approaches to identify genetic diagnoses focus almost exclusively on regions of the genome that directly encode proteins, even when genome sequencing data are available. In this talk, I will discuss how studying gene regulation and genetic variants in regions of the genome that are exonic, but do not encode proteins (i.e. untranslated regions and non-coding RNAs) can identify new diagnoses for rare disease patients and help to develop treatments.

Watch now!

S1 E3 - Wednesday, April 30, 2025 (16:00 CEST)

true

Zoltan Kutalik
University of Lausanne
Switzerland

Making sense of genetic associations

Genome-wide association studies have generated tens of thousands of associations between complex diseases and sequence variants. Despite the remarkable efforts of the past 15 years, the interpretation of these links and their clinical translation remains elusive.

I will explain how these vast amount of associations can be combined together (via extensions of the Mendelian Randomisation principle) in various fashions to learn about meaningful epidemiological phenomena (different disease consequences of various obesity subtypes), human behaviour (partner choice, parental rearing), biases in the data collection (due to study participation behaviour, self reporting errors), drug target- / biomarker genes.

Watch now!

S1 E4 - Wednesday, June 25, 2025 (16:00 CEST)

true

Kaitlin Samocha
Massachusetts General Hospital
United States of America

Leveraging population data to improve variant interpretation

One of the primary challenges in human genomics is the ability to interpret genetic variation. Publicly available databases of human sequencing data from reference populations are important resources, most notably because they provide allele frequency information that can be used to filter variants. The patterns of variation observed in these reference populations can also be used to identify genes, or genomic regions, that are intolerant of mutations. In this talk, I will cover how analyzing large genomic datasets from reference populations can aid in variant interpretation, specifically in the context of rare disease.

Watch now!

S1 E5 - Wednesday, July 30, 2025 (16:00 CEST)

true

Siddharth Banka
University of Manchester
UK

From Chromatinopathies to Episignatures

Chromatin enables packaging of DNA into nuclei and is critical for many biological processes ranging from gene expression to cell division. Chromatin structure and activity is controlled by several hundred molecules. Mutations in genes encoding factors that regulate chromatin result in Mendelian disorders, that we now designate as 'chromatinopathies'. Collectively, chromatinopathies are responsible for a substantial proportion of rare genetic disorders. In recent years, DNA methylation related 'episignatures' have been discovered for several chromatinopthies. In this presentation, I will describe the biological classification of chromatinopathies, provide an overview of their common clinical characteristics and discuss the role of episignatures in their diagnosis.

Watch now!

S1 E6 - Wednesday, September 24, 2025 (16:00 CEST)

true

Serena Nik-Zainal
University of Cambridge
UK

Recent advances in mutational signatures and clinical applications

Mutational signatures are patterns of mutations that arise in DNA because of the processes that are occurring within a cell, in normal and cancer cells. Over the last decade this field has grown substantially, thanks to the enormous increase in scale offered by whole genome sequencing (WGS) projects wordlwide. In this talk, I will present some new developments in the field, including how they can be used for clinical purposes.

Watch now!

S1 E7 - Wednesday, October 29, 2025 (16:00 CET)

true

Elfride de Baere
Ghent University (Hospital)
Belgium

Multi-omics in inherited eye diseases: from missing heritability to new therapeutic opportunities

Inherited eye diseases (IED) are a major cause of early-onset blindness and vision loss. A crucial step in their management is achieving a definitive genetic diagnosis and understanding disease pathogenesis. While advances in genomics have substantially improved IED diagnostics, many variants remain either difficult-to-detect or difficult-to-interpret, leading to missing heritability.
In this talk, I will highlight a multi-omics framework to advance diagnosis in IED, integrating short-read and single-molecule genomics, transcriptomics (RNA-seq), and epigenomics. Addressing missing heritability not only improves diagnosis but also opens the door to new therapeutic opportunities.

Watch now!

S1 E8 - Wednesday, November 26, 2025 (16:00 CET)

true

Lisenka Vissers
Radboudumc
The Netherlands

Translating long read genome sequencing to clinical applications for rare diseases

Long-read genome sequencing (lrGS) has, in recent years, undergone substantial improvements in both throughput and accuracy. This technology now enables comprehensive detection of essentially all classes of genetic variation within a single experiment, with the potential to replace most, if not all, current workflows used in germline-based diagnostic testing for rare diseases. In this presentation, I will discuss clinical utility studies designed to evaluate the real-world value of implementing lrGS in clinical practice. Specifically, I will address two ends of the implementation spectrum: the opportunity to enhance laboratory efficiency and, more importantly, the capacity of lrGS to increase diagnostic yield in rare diseases.

Watch now!

S2 E1 - Wednesday, January 28, 2026 (14:00 CET)

true

Sarah Norris
The University of Sydney
Australia

The benefits, risks and challenges of sequencing the genome of newborns

Sarah will present findings from an Australian government funded project (genomics4newborns) that is exploring the perspectives of local stakeholders regarding the use of genomics in newborn bloodspot screening, and the circumstances under which this might be acceptable. The project is using qualitative, quantitative and deliberative methods to explore and compare the views of parents, scientists, clinicians, policy-makers, the general public, and Indigenous Australians. The integrated findings will be used to inform the development of a set of nationally-agreed principles to guide future decisions regarding the use of genomics in Australian newborn screening programs.

Link to the project: https://genomics4newborns.sydney.edu.au/

Watch now!

S2 E2 - Wednesday, February 25, 2026 (16:00 CET)

Newborn screening aims to avoid irreparable health damage by early diagnosis of (often genetic) conditions. It all started with phenylketonuria more than 50 years ago, but programs now cover 10-50 conditions. Many pilots of genomic newborn screening are ongoing, hoping to identify many more treatable conditions. This webinar will not just consist of one presentation, but it will briefly discuss some of the pros and cons. The first presentation will speak about the development of genomic newborn screening in England, followed by comments from the perspectives of patients and traditional newborn screening.

true

Amanda Pichini
Genomics England
UK

The Generation Study: exploring the potential of newborn genome sequencing in a national public health system 

The Generation Study is exploring the feasibility, acceptability and utility of sequencing the genomes of 100,000 babies to screen for >200 rare conditions; as well as use of babies’ genomes over their lifetimes for other clinical uses, and alongside longitudinal health data collection for wider health research. Early results from over 20,000 of newborns demonstrate detectability of treatable conditions while minimizing false positives. This talk will focus on the engagement, governance frameworks, ethical considerations and co-design approaches that have enabled sustainable and scalable implementation, as well as challenges in generating evidence and maintaining ongoing public trust. 

true

James R Bonham
President of the International Society of Neonatal Screening 
UK

Newborn Screening, much to explore, and also much to protect

Newborn screening is widely recognised as one of the greatest public health advances of the 20th century, with more than 750 million babies tested since its introduction and exceptionally high public confidence reflected in uptake rates exceeding 99%. Despite this success, current screening programmes identify fewer than 100 conditions, while thousands of congenital genetic disorders with potential treatments exist. Genomic newborn screening offers promising opportunities to expand detection, but also raises challenges related to variant interpretation, uncertainty in asymptomatic individuals, and reduced sensitivity in some populations; combining genomic and biochemical approaches may help extend screening responsibly while preserving accuracy and public trust.

true

Gulcin Gumus
EURORDIS - Rare Diseases Europe 
Spain

Shaping genetic newborn screening research through patient organisations

This talk will focus on how patient organisations can drive genetic newborn screening research forward, and on the role of EURORDIS in ensuring that patient perspectives are meaningfully included in the discussions that shape gNBS research today and gNBS practices in the future.

Watch now

S2 E3 - Wednesday, March 25, 2026 (16:00 CET)

true

Lili Milani
University of Tartu 
Estonia

Pharmacogenomic studies in the Estonian Biobank

Long-read sequencing technologies are transforming our ability to detect and interpret complex genetic variation, with important implications for both research and clinical implementation. In this webinar, I will present results from large-scale long-read genome sequencing in the Estonian Biobank, a volunteer-based resource linking genomic data with extensive electronic health records for over 212,000 participants. Sequencing of 10,000 genomes using PacBio HiFi technology has revealed a substantial number of novel variants and provided improved resolution of structural variants and complex pharmacogenomic loci that are often missed by short-read approaches. The talk will highlight insights from the CYP2D6-CYP2D7 region, demonstrating how long-read data enable accurate phasing and interpretation of clinically relevant haplotypes. In addition, the webinar will discuss the return of genomic results to participants through the MyGenome portal, which provides personalised pharmacogenetic and disease risk information and has already been accessed by more than 110,000 individuals.

Watch now

S2 E4 - Wednesday, April 29, 2026 (16:00 CEST)

true

Alexandre Reymond
University of Lausanne
Switzerland

Variable expressivity and pleiotropy of the 16p11.2 recurrent CNVs

Recurrent genomic rearrangements at 16p11.2 BP4-5 represent one of the most common causes of genomic disorders. Originally associated with increased risk for autism spectrum disorder, schizophrenia, developmental delay/intellectual disability, adiposity and altered head circumference, these CNVs have since been associated with a large array of phenotypic alterations with variable expressivity and penetrance. The encompassed genes act through both direct and indirect pleiotropy.
The 16p11.2 BP4-5 rearrangements are deleterious enough to be enriched in clinical cohorts but not enough so to be absent from population cohorts.

Watch now

S2 E5 - Wednesday, May 27, 2026 (16:00 CEST)

Industry Pathways in Genetics and Genomic Science

Jointly hosted by ASHG and ESHG, this 1-hour program provides an in depth look at how scientists build careers in the industry sector. Presenters will share how they apply their scientific background to the industry environment and offer advice to those considering this path. 

During this interactive panel discussion, speakers will explore: 

  • Pathways into the private sector 
  • The range of scientific roles in industry, including research, translational science, clinical development, and data science
  • Skills, experiences, and competencies that are most useful in their role 
  • Advice for trainees and early-career scientists preparing for industry careers

Following the panel, attendees will have the opportunity to ask questions and gain candid insights directly from industry scientists. 

Registration is free, but mandatory through the ASHG website:

  1. follow this link: https://learning.ashg.org/products/industry-pathways-in-genetics-and-genomic-science
  2. click on Register
  3. click on Log in
  4. click on 'Need an Account?' and fill out your information
  5. After creating the account, you will automatically have the webinar in your Dashboard

S2 E6 - Wednesday, July 29, 2026 (16:00 CEST)

true

Karoline Kuchenbäcker
University College London
UK

Ancestral diversity in genetics: From discovery to translation 

The expansion of ancestrally diverse genetic cohorts has altered the landscape of complex disease genetics. I will discuss how ancestral and global diversity shape genetic discoveries. Whilst there is widespread sharing of genetic architecture across ancestries, loci that display heterogeneity in causal genetic effects across populations can offer unique biological insights. As we advance towards global precision medicine, integrating genomic data with diverse environmental and social factors is crucial to account for population-specific contexts that can influence disease risk or treatment response.

Watch now

S2 E7 - Wednesday, September 30, 2026 (16:00 CEST)

ASHG-ESHG Joint Webinar: Careers in the Public Sector

Jointly hosted by ASHG and ESHG, this 1-hour program provides an in-depth look at how scientists build careers in the public sector. Presenters will share how they apply their scientific background to public sector roles and offer advice to those considering this path.

During this interactive panel discussion, speakers will explore:

  • Pathways into the public sector
  • The range of scientific roles in the public sector, including public health genomics, regulatory science, national screening programmes, and policy advising
  • Skills, experiences, and competencies that are most useful in their role
  • Advice for trainees and early-career scientists preparing for public sector careers

Following the panel, attendees will have the opportunity to ask questions and gain candid insights directly from scientists working in the public sector.

Speakers

true

Amna Khamis
University of Lille
France 

Amna Khamis is Professor at the University of Lille, Visiting Researcher at Imperial College London, and an EFSD/Novo Nordisk Foundation Future Leader Fellow. She studied and trained in genetics in the United Kingdom before moving to France, where she continued her academic career within the French public research and university system. She currently leads the Epigenomics group within the METAB-OMICS laboratory at the University of Lille, France. Her research focuses on the genomics and epigenomics of diabetes, ageing and metabolic disease using computational approaches, and on translating molecular discoveries into improved disease prediction and prevention.

true

Ayse Demirkan 
University of Surrey
UK

Dr Ayse Demirkan is an academic at the University of Surrey, where she has been working since 2021. She began her academic journey studying Biological Oceanography in University of Istanbul, before moving into wet-lab genetics and later developing expertise in genetic epidemiology, statistical genetics and multi-omics. In the Netherlands, she trained in genetic epidemiology at Erasmus MC and continued her research as a postdoctoral scientist at Leiden University. She has also held visiting appointments at Oxford Better Value Healthcare, Mount Sinai Hospital in New York and Groningen University Medical Centre.

Her research has evolved from understanding genetic variation and disease mechanisms to applying artificial intelligence for health and personalised medicine. In the UK, she leads and contributes to interdisciplinary work combining genetics, omics, clinical data and AI to improve disease prediction, biological interpretation and healthcare outcomes

true

Michael Talkowski
Harvard Medical School
US

Dr. Talkowski is the Director of the Center for Genomic Medicine (CGM) and Professor of Neurology at
Massachusetts General Hospital, Harvard Medical School (HMS), and the Mass General Brigham (MGB) Neuroscience Institute. He is also an Institute Member in the Program in Medical and Population Genetics and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard.

The CGM is a large, cross-departmental genomics hub of 80+ HMS affiliated faculty and over 400 genome scientists pursuing all facets of genomic medicine research across MGB and HMS Departments, Institutes, and Institutions. The CGM is a major docking point for institutional leadership and research programs at the Broad
Institute, as well as the neurogenetics and precision therapeutics programs of the MGB Neuroscience Institute.

Dr. Talkowski leads an integrated molecular and computational genomics research program focused on the discovery and characterization of genetic variation in human disease, mechanistic modeling, and the delivery of novel translational therapeutic and diagnostic approaches in genomic medicine. His team has been recognized for transformative discoveries the study of genome structural variation and the genetic etiologies of autism, neurodevelopmental and neuropsychiatric disorders, neurodegenerative disorders, and fetal anomalies.

Watch now 

S2 E8 - Wednesday, October 28, 2026 (16:00 CET)

Jointly hosted by ICHG and ESHG

Download the flyer for more information

true

Simoni Avansini
University of Campinas
Brasil

Stem cell-based organoid models of neurodevelopmental disorders

Neurodevelopmental disorders (NDDs) associated with epilepsy are complex, polygenic conditions with limited therapeutic options, mainly due to an incomplete understanding of their genetic basis and the lack of representative human models. In this presentation, I will discuss the use of human brain organoids derived from induced pluripotent stem cells of NDD patients. I will also present findings from brain organoids generated from patients with Focal Cortical Dysplasia, which recapitulate key disease hallmarks, including impaired proliferation, cellular abnormalities, and neuronal network hyperexcitability. These models provide a relevant platform to investigate disease mechanisms and enable therapeutic screening.

Dr. Avansini is a researcher at the University of Campinas (Brazil), where her work focuses on epilepsy, molecular biology, malformations of cortical development, and disease modeling using stem cells. Since 2010, she has been studying focal cortical dysplasia (FCD), aiming to understand the pathophysiology of this cortical malformation and ultimately accelerate the development of new treatments. Recently, she began her career as an independent researcher, with a particular interest in neurodevelopment and, more specifically, epileptogenesis in FCD using human brain models. Her contributions to science are focused on epilepsy and malformations of cortical development using molecular biology, genetics, and stem cell biology. She has published 17 full papers in peer-reviewed journals, with 902 citations and an H-index of 14 according to Google Scholar.

true

Andres Moreno-Estrada
Cinvestav South Campus
Mexico City

"Population medical genomics in Latin America: The Mexican Biobank Project"

Dr. Andres Moreno-Estrada is a leading researcher in population and evolutionary genomics whose work has significantly advanced the understanding of genetic diversity in Latin America. He led the first comprehensive study of the genetic structure of the Mexican population, including the genomes of 20 Indigenous groups, published in Science in 2014. His research demonstrated how regional Indigenous ancestry shapes the genetic diversity of Mexico’s cosmopolitan population and influences biomedical traits.

He has since expanded similar genomic studies across the Caribbean, South America, and Polynesia, including landmark research on the Rapanui population of Easter Island published in Nature in 2020. He currently leads the MX Biobank project, creating the most comprehensive genomic catalogue of the Mexican population, featured in Nature and Nature Medicine.

Dr. Moreno-Estrada has published more than 55 peer-reviewed papers with over 32,000 citations and has contributed to major international initiatives including the 1000 Genomes Project and the Human Cell Atlas. He is currently Principal Investigator of the Population and Evolutionary Genomics Laboratory at Cinvestav in Mexico City.

Watch now 

Contact

Ms. Magdalena Seidl
ESHG Society Office
c/o WMA GmbH, Alser Strasse 4, 1090 Vienna, Austria

[e]: courses(at)eshg.org